Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Leishmania major | hypothetical protein, conserved | 0.0025 | 0.0512 | 0.5 |
Brugia malayi | RNA recognition motif domain containing protein | 0.013 | 0.6692 | 0.6692 |
Echinococcus granulosus | guanine nucleotide binding protein Gs subunit | 0.0186 | 1 | 1 |
Brugia malayi | hypothetical protein | 0.0025 | 0.0512 | 0.0512 |
Loa Loa (eye worm) | RNA binding protein | 0.013 | 0.6692 | 0.6513 |
Loa Loa (eye worm) | hypothetical protein | 0.0032 | 0.0936 | 0.0447 |
Schistosoma mansoni | hypothetical protein | 0.0069 | 0.3105 | 0.2393 |
Trypanosoma cruzi | PAB1-binding protein , putative | 0.0025 | 0.0512 | 0.5 |
Loa Loa (eye worm) | pigment dispersing factor receptor c | 0.0101 | 0.4974 | 0.4702 |
Brugia malayi | MH2 domain containing protein | 0.0116 | 0.5845 | 0.5845 |
Echinococcus multilocularis | tar DNA binding protein | 0.013 | 0.6692 | 0.635 |
Brugia malayi | latrophilin 2 splice variant baaae | 0.0069 | 0.3105 | 0.3105 |
Trypanosoma cruzi | PAB1-binding protein , putative | 0.0025 | 0.0512 | 0.5 |
Loa Loa (eye worm) | transcription factor SMAD2 | 0.0116 | 0.5845 | 0.5621 |
Plasmodium falciparum | ataxin-2 like protein, putative | 0.0025 | 0.0512 | 0.5 |
Schistosoma mansoni | tar DNA-binding protein | 0.013 | 0.6692 | 0.635 |
Echinococcus granulosus | tar DNA binding protein | 0.013 | 0.6692 | 0.635 |
Brugia malayi | Latrophilin receptor protein 2 | 0.0032 | 0.0936 | 0.0936 |
Toxoplasma gondii | LsmAD domain-containing protein | 0.0025 | 0.0512 | 0.5 |
Echinococcus multilocularis | guanine nucleotide binding protein G(s) subunit | 0.0186 | 1 | 1 |
Brugia malayi | TAR-binding protein | 0.013 | 0.6692 | 0.6692 |
Trypanosoma brucei | PAB1-binding protein , putative | 0.0025 | 0.0512 | 0.5 |
Schistosoma mansoni | Guanine nucleotide-binding protein G(s) subunit alpha (Adenylate cyclase-stimulating G alpha protein) | 0.0186 | 1 | 1 |
Schistosoma mansoni | tar DNA-binding protein | 0.013 | 0.6692 | 0.635 |
Loa Loa (eye worm) | MH2 domain-containing protein | 0.0116 | 0.5845 | 0.5621 |
Plasmodium vivax | ataxin-2 like protein, putative | 0.0025 | 0.0512 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0101 | 0.4974 | 0.4702 |
Brugia malayi | RNA binding protein | 0.013 | 0.6692 | 0.6692 |
Echinococcus multilocularis | guanine nucleotide binding protein G(s) subunit | 0.0186 | 1 | 1 |
Plasmodium falciparum | ataxin-2 like protein, putative | 0.0025 | 0.0512 | 0.5 |
Brugia malayi | Calcitonin receptor-like protein seb-1 | 0.0101 | 0.4974 | 0.4974 |
Brugia malayi | Corticotropin releasing factor receptor 2 precursor, putative | 0.0101 | 0.4974 | 0.4974 |
Schistosoma mansoni | tar DNA-binding protein | 0.013 | 0.6692 | 0.635 |
Loa Loa (eye worm) | RNA recognition domain-containing protein domain-containing protein | 0.013 | 0.6692 | 0.6513 |
Schistosoma mansoni | Guanine nucleotide-binding protein G(s) subunit alpha (Adenylate cyclase-stimulating G alpha protein) | 0.0186 | 1 | 1 |
Echinococcus granulosus | guanine nucleotide binding protein Gs subunit | 0.0186 | 1 | 1 |
Schistosoma mansoni | tar DNA-binding protein | 0.013 | 0.6692 | 0.635 |
Schistosoma mansoni | Guanine nucleotide-binding protein G(s) subunit alpha (Adenylate cyclase-stimulating G alpha protein) | 0.0186 | 1 | 1 |
Loa Loa (eye worm) | latrophilin receptor protein 2 | 0.0032 | 0.0936 | 0.0447 |
Loa Loa (eye worm) | GTP-binding regulatory protein Gs alpha-S chain | 0.0186 | 1 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0069 | 0.3105 | 0.2733 |
Schistosoma mansoni | tar DNA-binding protein | 0.013 | 0.6692 | 0.635 |
Loa Loa (eye worm) | TAR-binding protein | 0.013 | 0.6692 | 0.6513 |
Brugia malayi | calcium-independent alpha-latrotoxin receptor 2, putative | 0.0032 | 0.0936 | 0.0936 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
ED50 (functional) | = 0.82 mg kg-1 | Compound was tested for Therapeutic effects on systemic infections on mice by peroral administration | ChEMBL. | 8064806 |
ED50 (functional) | = 1.09 mg kg-1 | Compound was tested for Therapeutic effects on systemic infections on mice by peroral administration | ChEMBL. | 8064806 |
ED50 (functional) | = 1.09 mg kg-1 | Compound was tested for Therapeutic effects on systemic infections on mice by peroral administration | ChEMBL. | 8064806 |
ED50 (functional) | = 1.25 mg kg-1 | Compound was tested for Therapeutic effects on systemic infections on mice by peroral administration | ChEMBL. | 8064806 |
ED50 (functional) | = 1.7 mg kg-1 | Compound was tested for oral efficacy on systemic infections on mice by peroral administration | ChEMBL. | 8064806 |
ED50 (functional) | = 1.7 mg kg-1 | Compound was tested for oral efficacy on systemic infections on mice by peroral administration | ChEMBL. | 8064806 |
MIC (functional) | = 0.006 ug ml-1 | Compound was tested for its minimal inhibitory constant against Gram-positive microorganism S. aureus IID 803 (Sa(I)) | ChEMBL. | 8064806 |
MIC (functional) | <= 0.006 ug ml-1 | Tested for in vitro for antibacterial activity against 16 clinical isolated of methicillin-resistant Staphylococcus aureus, range of Minimal inhibitory activity value for isolates | ChEMBL. | 8064806 |
MIC (functional) | = 0.0125 ug ml-1 | Compound was tested for its minimal inhibitory constant against Gram-positive microorganism S. aureus IID 803 (Sa(I)) | ChEMBL. | 8064806 |
MIC (functional) | = 0.025 ug ml-1 | Compound was tested for its minimal inhibitory constant against Gram-positive microorganism Staphylococcus aureus FDA 209P JC-1 (Sa(F)) | ChEMBL. | 8064806 |
MIC (functional) | = 0.025 ug ml-1 | Compound was tested for its minimal inhibitory constant against Gram-positive microorganism S. epidermis IAM 1296 (Se) | ChEMBL. | 8064806 |
MIC (functional) | = 0.05 ug ml-1 | Compound was tested for its minimal inhibitory constant against Gram-positive microorganism S. epidermis IAM 1296 (Se) | ChEMBL. | 8064806 |
MIC (functional) | = 0.2 ug ml-1 | Compound was tested for its minimal inhibitory constant against Gram-positive microorganism E. faecalis IID682 (Ef) | ChEMBL. | 8064806 |
MIC (functional) | = 0.2 ug ml-1 | Compound was tested for its minimal inhibitory constant against Gram-positive microorganism M. luteus ATCC 9341 (MI) | ChEMBL. | 8064806 |
MIC (functional) | = 0.2 ug ml-1 | Compound was tested for its minimal inhibitory constant against Gram-negative microorganism E. coli NIHJ JC-2 (Ec(N)) | ChEMBL. | 8064806 |
MIC (functional) | = 0.2 ug ml-1 | Compound was tested for its minimal inhibitory constant against Gram-negative microorganism E. coli NIHJ JC-2 (Ec(N)) | ChEMBL. | 8064806 |
MIC (functional) | = 0.39 ug ml-1 | Compound was tested for its minimal inhibitory constant against Gram-negative microorganism E. coli NIHJ JC-2 (Ec(N)) | ChEMBL. | 8064806 |
MIC (functional) | = 0.39 ug ml-1 | Compound was tested for its minimal inhibitory constant against Gram-negative microorganism E. coli KC-14 (Ec(K)) | ChEMBL. | 8064806 |
MIC (functional) | = 0.39 ug ml-1 | Compound was tested for its minimal inhibitory constant against Gram-negative microorganism K. pneumoniae B54 (Kp) | ChEMBL. | 8064806 |
MIC (functional) | = 0.39 ug ml-1 | Compound was tested for its minimal inhibitory constant against Gram-negative microorganism E. coli KC-14 (Ec(K)) | ChEMBL. | 8064806 |
MIC (functional) | = 0.78 ug ml-1 | Compound was tested for its minimal inhibitory constant against Gram-negative microorganism K. pneumoniae B54 (Kp) | ChEMBL. | 8064806 |
MIC (functional) | = 3.13 ug ml-1 | Compound was tested for its minimal inhibitory constant against Gram-negative microorganism P. aeruginosa IFO 3445 (Pa(I)) | ChEMBL. | 8064806 |
MIC (functional) | = 3.13 ug ml-1 | Compound was tested for its minimal inhibitory constant against Gram-negative microorganism P. aeruginosa E-2 (Pa(E)) | ChEMBL. | 8064806 |
MIC50 (functional) | = 0.39 ug ml-1 | Tested for in vitro for antibacterial activity against 16 clinical isolated of methicillin-resistant Staphylococcus aureus | ChEMBL. | 8064806 |
MIC90 (functional) | = 0.78 ug ml-1 | Tested for in vitro for antibacterial activity against 16 clinical isolated of methicillin-resistant Staphylococcus aureus | ChEMBL. | 8064806 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.